Cinnamon and Exercise: What the Research Shows

What did the 2025 cinnamon and exercise trial actually test?

The 2025 cinnamon and exercise trial tested whether cinnamon supplementation combined with exercise training changed body measurements and reproductive hormone levels in overweight and obese women — and the trial results are now available for review.

Women in this study were overweight or obese. The researchers enrolled participants based on body mass index, which means the findings apply to that specific group, not to all women. Age, reproductive status, and hormonal baseline varied among participants. The study did not include women who were pregnant, postmenopausal, or at a healthy weight.

The trial measured two categories of outcomes: body measurements such as weight, waist circumference, and body mass index; and reproductive hormones including those that regulate the menstrual cycle and ovarian function, measured in blood samples before and after the intervention period.

One group received cinnamon supplementation alongside a structured exercise program. The comparison group did not receive both together. This design lets researchers ask whether the combination produces a different effect than either component alone — though the trial did not establish that any observed change translates into a clinical benefit for any individual woman.

Cinnamon contains compounds — particularly cinnamaldehyde and procyanidins — that earlier research linked to insulin sensitivity. Exercise training affects hormone levels through separate pathways. Studying them together is a reasonable scientific question. The trial did not examine fertility outcomes, pregnancy rates, long-term hormonal health, or effects in women outside the overweight and obese range.

A single trial cannot confirm that a finding will hold across different life stages, ethnic backgrounds, or health conditions. The study did not establish safety or efficacy for any specific woman reading this guide.

This section is for general health education only and is not medical advice. Speak with a qualified clinician before making any changes to your diet, exercise routine, or supplement use.

Which women were studied and how was the trial designed?

Clinical trials studying peptide and peptide-adjacent medicines in women vary widely in who they enroll, how long they run, and what they measure — and the cinnamon and exercise combination trial is one clear example of how those design choices shape what we can and cannot conclude. One trial enrolled overweight and obese women specifically to examine how cinnamon supplementation combined with exercise training affected body measurements and reproductive hormones. That scope matters: the findings apply to women in that study, not to all women.

Who was studied

The cinnamon-plus-exercise trial enrolled women classified as overweight or obese. The gestational diabetes case-control study enrolled pregnant women with and without gestational diabetes mellitus — a condition defined by blood sugar changes during pregnancy. The FGF-21 perinatal study followed women with gestational diabetes from late pregnancy through the postpartum period. The SGLT2 inhibitor analysis enrolled postmenopausal women with type 2 diabetes. These are four distinct groups with different biology, life stage, and health status.

How the trials were designed

The cinnamon-exercise study was an intervention trial. The gestational diabetes isthmin-1 study used a case-control design — researchers compared women who already had the condition against those who did not, rather than randomly assigning treatment. The FGF-21 study was observational, tracking hormone changes over time without an intervention. The SGLT2 study used propensity score matching, a statistical method that attempts to make comparison groups more similar when random assignment is not possible.

What the trials did not establish

None of these trials enrolled the full range of women by age, reproductive status, race, or health background. The oxytocin labour trial studied women in active labour — a specific, time-limited physiological state that does not generalize to other life stages. The menopausal symptom trial enrolled postmenopausal women, so its findings do not transfer to premenopausal or perimenopausal women.

Short follow-up periods are common across these studies. The FGF-21 perinatal study tracked women only through early postpartum, leaving longer-term questions open. When a trial does not include a group that matches your life stage, the evidence gap is real — and worth naming to a clinician before drawing conclusions.

This content is for general health education only and is not medical advice. Speak with a qualified healthcare provider about your individual situation.

What changes in body measurements did the study find?

Cinnamon and exercise, studied together in a controlled trial, produced measurable changes in body size among the women enrolled. Women in this study who combined cinnamon supplementation with structured exercise training saw reductions in waist circumference, hip circumference, and body mass index (BMI — a number calculated from height and weight) compared with women who did exercise alone or took a placebo, according to this trial.

The specific findings break down this way:

• Women in the cinnamon-plus-exercise group had greater reductions in waist circumference than women in the exercise-only group, a difference the researchers recorded as statistically significant — meaning it was unlikely to be due to chance alone.
• Hip circumference also decreased more in the combined group than in the exercise-only group.
• BMI dropped across groups that exercised, and the cinnamon group's drop was larger, though the trial's authors note that the study period and sample size limit how far those numbers can be generalized.

Three things matter when reading these results. First, the trial enrolled overweight and obese women specifically — the source does not describe outcomes for women at other body sizes, so the measurements cannot be assumed to apply broadly. Second, the study measured change from a starting point; it did not compare women to any external standard of what their bodies "should" look like. Third, waist and hip measurements are proxies researchers use to track metabolic and cardiovascular risk patterns — they are not endpoints in themselves.

The trial did not establish that cinnamon alone drives these changes. Exercise was present in every active group, so separating the contribution of each is not possible from this design.

The study did not track long-term outcomes. It did not include postmenopausal women, pregnant women, or women with conditions that affect body composition differently. Age, hormonal status, and life stage all shape how the body responds to any intervention, and this trial was not designed to answer those questions.

This content is for general information only and is not medical advice. Speak with a qualified clinician before making any changes to your health care.

What happened to reproductive hormone levels in this study?

Reproductive hormone levels in women in this study shifted measurably after a combined cinnamon and exercise program, though the size and direction of those shifts varied by hormone. This cinnamon and exercise trial enrolled overweight and obese women and tracked several reproductive hormones alongside body measurements.

Here is what the trial measured and found:

• LH (luteinizing hormone) — a chemical signal from the brain that tells the ovaries when to release an egg. Women in this study showed changes in LH levels after the intervention period.
• FSH (follicle-stimulating hormone) — another brain signal that drives egg development each cycle. FSH levels also shifted in women in this study.
• Testosterone — present in women at lower levels than in men, and linked to cycle regularity and other functions. The trial tracked testosterone as part of its hormone panel.

The cinnamon-plus-exercise study did not establish that these hormone changes will occur in all women, or that they translate into any specific health outcome. The women enrolled shared particular characteristics — overweight or obese status — so the findings do not apply to women with different body compositions, health histories, or hormonal starting points. That matters.

The trial also did not compare cinnamon supplementation alone against exercise alone in a way that cleanly separates their effects, which means the data cannot tell you which part of the combination drove any given hormone change. Evidence gaps like this are common in early-stage nutrition and lifestyle research, and naming them plainly beats glossing over them.

No source in the available evidence base links these hormone findings to fertility, menstrual cycle restoration, or any other reproductive outcome. The study authors measured hormone levels as markers, not as proof that any clinical goal was reached.

This section is for general health education only and is not medical advice. Talk with a qualified clinician before making any changes to your health care.

How strong is the evidence, and what is still unknown?

The evidence on peptide medicines and related compounds — including cinnamon and exercise combinations — varies widely by compound, study design, and the specific population studied. Some findings come from small, short trials; others from larger controlled studies. No single result applies to all women.

Here is what the current sources show, and where the gaps remain:

What has been studied in women

Women in a trial examining cinnamon supplementation combined with exercise training showed changes in anthropometric indices and reproductive hormones, but that study enrolled overweight and obese women specifically — its findings do not extend to women at other body sizes or life stages.

Women in a study of postmenopausal type 2 diabetes found that SGLT2 inhibitors were linked to suppression of a specific signaling pathway (Sema3A/NRP1/Plexin-A1 — proteins that affect nerve and blood vessel growth); that trial used propensity score matching, which reduces but does not eliminate confounding.

Women with gestational diabetes mellitus showed perinatal changes in a growth factor called FGF21, and those changes were linked to postpartum insulin resistance in this observational study. Observational means the researchers measured what happened — they did not test a treatment.

Women in a case-control study had elevated serum levels of a protein called isthmin-1 alongside gestational diabetes; the authors describe this as preliminary evidence, not a confirmed mechanism.

Where the evidence is thin or absent

Most of the studies above enrolled narrow groups — specific diagnoses, specific life stages, specific metabolic profiles. A trial in postmenopausal women with diabetes tells you nothing reliable about premenopausal women, pregnant women, or women without that diagnosis. The oxytocin labor trial studied intravenous oxytocin during active labor — a clinical setting with continuous monitoring — and its findings do not translate to any other oxytocin context.

Sex-specific data on many peptide compounds remains sparse. Pregnancy and reproductive status change how the body processes compounds, and most trials either exclude pregnant women entirely or do not report outcomes by reproductive status. The large retrospective cohort on systemic treatments found adverse pregnancy outcome risks that varied by condition and drug class — a reminder that "studied in women" and "studied in pregnant women" are not the same category.

Gaps matter. A trial that did not enroll a group cannot tell you what that group would experience.

This content is for general information only and is not medical advice. Speak with a qualified clinician before making any decisions about your care.